Prime Capital Investment Advisors LLC Acquires Shares of 6,835 Valeant Pharmaceuticals Intl Inc (VRX)
Prime Capital Investment Advisors LLC acquired a new position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) in the 4th quarter, HoldingsChannel reports. The firm acquired 6,835 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000.
Other large investors have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. lifted its stake in Valeant Pharmaceuticals Intl by 55.0% during the third quarter. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company’s stock worth $337,000 after purchasing an additional 8,400 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Valeant Pharmaceuticals Intl by 53.9% during the fourth quarter. Acadian Asset Management LLC now owns 368,617 shares of the specialty pharmaceutical company’s stock worth $7,708,000 after purchasing an additional 129,092 shares in the last quarter. Quadrant Private Wealth Management LLC acquired a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth $357,000. Kovack Advisors Inc. acquired a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth $405,000. Finally, Nationwide Fund Advisors lifted its stake in Valeant Pharmaceuticals Intl by 25.0% during the third quarter. Nationwide Fund Advisors now owns 65,480 shares of the specialty pharmaceutical company’s stock worth $938,000 after purchasing an additional 13,080 shares in the last quarter. Institutional investors own 49.75% of the company’s stock.
In other Valeant Pharmaceuticals Intl news, Director John Paulson purchased 7,066,629 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were bought at an average cost of $15.40 per share, for a total transaction of $108,826,086.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.87% of the stock is owned by company insiders.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.18 billion. During the same period last year, the firm earned $1.26 earnings per share. Valeant Pharmaceuticals Intl’s quarterly revenue was down 10.0% on a year-over-year basis. equities research analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.12 EPS for the current year.
A number of research analysts have commented on the company. Deutsche Bank set a $20.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “hold” rating in a research note on Wednesday, February 21st. ValuEngine upgraded Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Wells Fargo & Co restated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, January 4th. TD Securities upped their price target on Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Goldman Sachs Group assumed coverage on Valeant Pharmaceuticals Intl in a research note on Wednesday, January 24th. They set a “sell” rating and a $18.00 price target on the stock. Seven analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $17.99.
ILLEGAL ACTIVITY NOTICE: “Prime Capital Investment Advisors LLC Acquires Shares of 6,835 Valeant Pharmaceuticals Intl Inc (VRX)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/03/11/prime-capital-investment-advisors-llc-acquires-shares-of-6835-valeant-pharmaceuticals-intl-inc-vrx.html.
Valeant Pharmaceuticals Intl Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.